For patients with metastatic triple negative breast cancer on nab-paclitaxel + atezolizumab who have an ongoing response, are you continuing immunotherapy after the FDA withdrawal of atezolizumab?

Yes, I would consider continuing immunotherapy. We know that the full benefit of immune checkpoint inhibitors may be delayed and may be durable as opposed to single agent chemotherapy. Even in patients with an early response to atezo and nab-paclitaxel, I would continue the combination if possible, provided no intolerable toxicity, for at least 2 years or even longer (the two years that we all use is totally arbitrary) as long as the patient continues to derive benefit. You can help the patient apply for free drug supply from Roche or you can try to obtain free pembrolizumab from Merck. I have been having very positive outcomes with our application for free drugs from Merck.